LONG-TERM anticoagulation is an accepted mode of treatment for prevention of emboli from fibrillating hearts, thrombotic occlusions in arteriosclerotic disorders, and pulmonary emboli in phlebitis. The degree of success in coronary artery disease is somewhat disappointing because it does not completely eradicate death from this cause although the incidence of thrombotic complications is clearly reduced.'-3 These results, of course, suggest that intravaseular coagulation plays a secondary although important role rather than a primary role as postulated by Duguid.4 The experience acquired during the past 15 years based on laboratory research and clinical observations has led to the establishment of a more or less safe technic of anticoagulant administration. In experienced hands the benefits derived from the use of anticoagulant drugs in carefully selected cases outweighs the risk from bleeding complications due to these drugs. Besides bleeding, as a major complication it has also been noted that discontinuance of treatment for one reason or another carried with it a risk of recurrence of a thrombotic condition. This has been called the rebound phenomenon. In this paper the term "rebound" refers to such post-anticoagulant thrombosis. Material and Methods From a consecutive series of 310 patients on long-term anticoagulant treatment with either phenindione or warfarin all patients were collected who had interrupted treatment for any reason and were divided into three groups. Group A consisted of those whose treatment was interrupted because of bleeding. Included were all instances in which the anticoagulant was stopped for 3 days or more, vitamin K, in a dose large enough to return the prothrombin time to normal was given, or the patient received a transfusion. Excluded were instances in which the anticoagulant was stopped for 1 or 2 days only. There were 45 instances in 43 patients, two patients having two episodes of bleeding.
Group B consisted of all those who gave up treatment permanently for one reason or another before the end of the period for which they were being treated. The reasons for stopping were either the patient discontinuing of his own choice, treatment discontinued by another medical facility because of a second unrelated disease, an operation in which the conditions did not warrant continuation, patient moved away, was unreliable, or could not get transportation to the laboratory. There were 53 instances in 52 patients, one patient gave up treatment of her own accord twice, but resumed it after the first period of abstinence because of a complication and stopped again. tify this conclusion. Death was considered to have been due to a vascular disorder unless the circuinstances clearly indicated that it was not. This free interpretation of a complication was necessary because in some instances in which the patient died suddenly at home there was only the history of the event on which to base the diagnosis. Twentyfour of the total of 38 complications were under circumstances in which the diagnosis could be definite (i.e., autopsy, electrocardiogram, paralytic stroke) and in the remaining 14 the diagnosis was empirical.
Details in regard to the composition of the three groups are shown in table 1. They were similar in age distribution, incidence of diabetes, and hypertension. There were a few more women in group B than in the other two groups. More patients were treated for peripheral emboli from the heart in group C and fewer patients were treated for coronary artery disease in group A. Thus, group C is a distinctly different group, but groups A and B are comparable. At least the differences are not sufficient to explain the results noted below.
Results
In group A there were 10 fatal and 10 nonfatal complications. Fourteen of the 20 complications happened within 4 weeks of stopCirculation, Volume XXIV, November 1961 ping treatment. This was a distinct difference from groups B and C and suggested a rebound effect.
In group B there were seven fatal and eight nonfatal complications. Only one complication happened ill the first 4 weeks, and this was nonfatal.
In group C there were only three complications, all of which were nonfatal. They consisted of an embolus to the leg in one patient with rheumatic heart disease 5 days after interruption of treatment for an appen dectomy, coronary insufficiency in a patient 5 days after interruption for a tooth extraction, and transient cerebral vascular insufficieney in a patient 7 days after interruption of treatment because it was thought that the anticoagulant preparation might be producing a syndrome of dry mouth. From the observations in groups B and C it appeared that interruption of treatment for short periods of time could be accomplished without a great risk. Because of its different composition group C was dropped from further considera- It is suggested that discontinuance of treatment early in the course of long-term anticoagulation might be accompanied by a higher complication rate than late discontinuance.' The possibility that patients in group A interrupted treatment earlier than those in group B was examined. The results indicated to the contrary that patients in group A had been on treatment slightly longer than those in group B before interruption. Those who had complications showed the same duration of treatment as those who did not. This applied in both groups (table 3) .
Since differences in the composition of the groups did not seem to explain adequately the early appearance of complications in group A, other explanations were sought. Administration of vitamin K, might induce a return to a hypercoagulable state. Transfusions with banked blood migpht introduce throinboplastic substances analogous to the clot-promoting property of serum described by Wessler.13 Tissue ischemia secondary to blood loss might 
